Beijing Bohui Innovation Technology Co Ltd - Asset Resilience Ratio
Beijing Bohui Innovation Technology Co Ltd (300318) has an Asset Resilience Ratio of 0.16% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Beijing Bohui Innovation Technology Co L strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2023)
This chart shows how Beijing Bohui Innovation Technology Co Ltd's Asset Resilience Ratio has changed over time. See 300318 equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Beijing Bohui Innovation Technology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Beijing Bohui Innovation Technology Co L (300318) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥6.98 Million | 0.16% |
| Total Liquid Assets | CN¥6.98 Million | 0.16% |
Asset Resilience Insights
- Limited Liquidity: Beijing Bohui Innovation Technology Co Ltd maintains only 0.16% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Beijing Bohui Innovation Technology Co Ltd Industry Peers by Asset Resilience Ratio
Compare Beijing Bohui Innovation Technology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Beijing Bohui Innovation Technology Co Ltd (2005–2023)
The table below shows the annual Asset Resilience Ratio data for Beijing Bohui Innovation Technology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -4.12% | CN¥-161.72 Million ≈ $-23.66 Million |
CN¥3.93 Billion ≈ $574.50 Million |
+1.35pp |
| 2022-12-31 | -5.47% | CN¥-213.82 Million ≈ $-31.29 Million |
CN¥3.91 Billion ≈ $571.86 Million |
-1.69pp |
| 2021-12-31 | -3.78% | CN¥-139.46 Million ≈ $-20.41 Million |
CN¥3.69 Billion ≈ $539.97 Million |
-1.75pp |
| 2020-12-31 | -2.03% | CN¥-75.57 Million ≈ $-11.06 Million |
CN¥3.72 Billion ≈ $543.66 Million |
+0.40pp |
| 2019-12-31 | -2.43% | CN¥-65.48 Million ≈ $-9.58 Million |
CN¥2.69 Billion ≈ $394.31 Million |
-0.12pp |
| 2018-12-31 | -2.31% | CN¥-62.63 Million ≈ $-9.17 Million |
CN¥2.71 Billion ≈ $396.90 Million |
-2.49pp |
| 2017-12-31 | 0.19% | CN¥5.07 Million ≈ $742.31K |
CN¥2.74 Billion ≈ $400.58 Million |
-45.78pp |
| 2007-12-31 | 45.97% | CN¥48.73 Million ≈ $7.13 Million |
CN¥106.00 Million ≈ $15.51 Million |
+42.99pp |
| 2006-12-31 | 2.98% | CN¥2.40 Million ≈ $351.20K |
CN¥80.53 Million ≈ $11.78 Million |
-56.27pp |
| 2005-12-31 | 59.25% | CN¥45.10 Million ≈ $6.60 Million |
CN¥76.12 Million ≈ $11.14 Million |
-- |
About Beijing Bohui Innovation Technology Co Ltd
Beijing Bohui Innovation Biotechnology Group Co., Ltd. engages in the research and development, production, sale, and after-sale service of diagnostic products in China. The company offers human immunoglobulin for rabies, tetanus, hepatitis B, and intravenous injections; albumin; human prothrombin complex; and vaccine for rabies. It also provides molecular platform, such as Automatic Real-time Fl… Read more